

Abstract Submission Rules and Guidelines

Abstract submission is free of charge and must be completed online via the M&PD 2026 Abstract Submission Portal (<https://medpoint.de/mpd-abstracts>). Abstracts sent by email will not be accepted.

Abstracts must be submitted by the abstract submission deadline of **18 August 2026**. Late submissions will not be accepted. You may save a draft of your submission at any time if it is incomplete and return to it later; a review section provides an overview of your entries before final submission. Once submitted, abstracts cannot be changed.

The ESC currently does not allow abstract submissions exclusively from Institutions in the Russian Federation and/or Belarus. However collaborative research may be submitted and (if accepted) presented by co-authors from other countries.

General Information

Changes and corrections – Once submitted, it is not possible to make any corrections to the abstract content or information (such as authors list and details, topic, conclusion(s) etc...). Neither the ESC nor the M&PD 2026 Organisational Team is authorised to make changes to a submission. In order to correct your abstract, you must withdraw it and submit a new version prior to the deadline (see below for withdrawal procedure). Note that such replacement of your abstract is not possible after the deadline. In the case of errors discovered after the deadline, you may indicate the correction on your presentation; however, changes will not be included in the publications (if applicable). If accepted, your abstract will be published as submitted.

Withdrawal – If you want to withdraw an abstract already submitted, please notify us as quickly as possible at mpd2026@medpoint.de, stating the title and reference number of the abstract to be withdrawn. Withdrawals are still accepted after the submission deadline.

Step 1: Abstract Information

Title – Maximum 50 words, typed in lower-case letters, except for study names and standard abbreviations. Please be careful that your title might be truncated if you copy and paste it into the field. Do not include authors, institutions, city names, or trademarks in the title.

Abstract submission topics – At the time of abstract submission, the submitter must select the topic(s) that best describe the abstract (Heart Muscle Diseases/Cardiomyopathies, Myocarditis, Pericardial Diseases/Pericarditis). It is important to carefully select the best matching topic(s), as this choice will determine under which area the abstract will be reviewed and graded.

Our mission: to reduce the burden of cardiovascular disease.

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIÉTÉ EUROPÉENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

Additional Information for the Oral/Awards Sessions – Note that by default the first author should be the presenter; if not, he/she needs to be able to explain his/her role in the research.

Accepted abstracts will be presented in a poster format during the event. In addition, a selection of the best posters will be presented orally in a specific session of the scientific programme. Presenters whose abstract is selected for presentation in an Oral session will receive specific instructions in due time. The results of the competition for Poster Awards will be announced during the Awards Ceremony. Each finalist will receive an Award certificate and a complimentary registration for next year's meeting. We highlight the fact that only the Presenter may have a prize & award certificate addressed to him/her.

On behalf of – You may use this field to enter the name of the affiliation for your research or the name of an investigating team. Do not use this field to list individual authors. Affiliation/investigating teams will not be listed in the authors' index of the Scientific Programme but will appear in publications (if applicable).

Trial Registration number – If available, indicate any reference to your trial registration.

Project code/Grant number – If any, please use this field to enter the information.

Funding acknowledgements – All sources of financial support (including government grants) for this research must be filed under this heading and not in the abstract text. All grant funding agency abbreviations should be spelt out. This information will be published in the abstract itself. The submitter is asked to indicate the type of funding source(s) and name it/them, if any. This information may be used in the context of ESC research projects.

Step 2: Abstract Authors and Institutions

Your abstract must list at least one author in order to be submitted.

Authors' list – Please note that the presenting author must be listed first in the authors list and must act as the contact author for the submission in the Abstract Submission Portal. The presenting author is responsible for ensuring that all co-authors have approved the content of the abstract before submission. The presenting author must be registered for the meeting before **28 September 2026** to ensure that the abstract is included in the programme and scheduled for presentation. In all cases, the Presenter must be part of the authors list included in the submitted abstract and be able to explain his/her role in the research during presentation.

You may enter up to 15 authors in the authors list including the Presenter. **If you have more than 15 authors, you can use the "On behalf of" field (see above) to enter the name of an investigating team/study group.**

Our mission: to reduce the burden of cardiovascular disease. 

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIETE EUROPEENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

The names of authors will be published as listed on the submission form. Please make sure you have entered the full list of authors – **Official contributors in the research submitted** – and that the information given for each author is correct, as **no changes** will be possible after the abstract is submitted (see paragraph on changes and corrections above).

The authors' order and details (names, cities, country codes) will be published as entered by the submitter. **An author may not revise or resubmit an abstract in order to make changes or corrections after this deadline; instead, the abstract may be withdrawn or, if accepted, the error may be indicated during the presentation. Adding or removing authors after the abstract submission deadline is not permitted.**

The submitter certifies and warrants to the ESC that the list of authors is complete and that he/she has permission from all persons he/she enters as co-authors to be listed in this abstract and that they are aware that their names will appear in all publications.

If the assigned presenter does not submit the abstract presentation in its required format by the deadline, the abstract will be automatically withdrawn and removed from the scientific programme and related publications.

Institutions/Affiliations – This is a mandatory step. You may list up to 10 affiliations, each with name, city, and country. All participating institutions should be listed as applicable. You will be requested to select the relevant affiliation(s) when you create the presenter and the authors.

Step 3: Abstract Content

All abstracts must be submitted (and will be presented) in English with accurate grammar and spelling suitable for publication. If in doubt, please arrange for the review of your abstract by a native English speaker, by a university scientific publications office (or other similar facility) prior to submission.

Submitted abstracts must contain original material neither published nor presented elsewhere. Please refer to the embargo policy below.

Abstracts that indicate "the work is in progress" or "the results will be announced/discussed in the presentation" cannot be accepted, as the reviewing committee needs full information to grade the submission and therefore will not be validated for the selection process.

Abstracts submitted on animal studies: the study must follow the "Principles of laboratory animal care" (NIH Publication no. 85-23, revised 1985) and the applicable national law.

Do not cut and paste symbols into your text. Use the symbols provided when you click on the Omega button (Ω).

Please paste the unformatted text of the abstract into the corresponding field. Standard special characters and symbols are supported.

Our mission: to reduce the burden of cardiovascular disease.

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIÉTÉ EUROPÉENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

Except for invited speakers, your abstract must follow this structure:

- Background
- Material and Methods
- Results
- Conclusions

Abstracts must not exceed 300 words and must be written in English. Please do not use blank lines to separate paragraphs. The word limit does not include the title and the authors – only the abstract text is taken into account.

Figure or Table (optional) – In addition to your text, you can attach a table, figure, image, or graphic as an optional file. You may upload up to 5 files.

- Format: PDF, PNG, or JPG
- Maximum size: 5 MB
- Minimum resolution: 300 dpi

Please make sure that your file(s) is (are) correctly uploaded and readable. It is the responsibility of the submitter to ensure the quality of the attachment(s) is suitable for publication – if not, file(s) of insufficient quality may be deleted.

Important: As the grading and selection process is blinded, the title and body text must not contain identifying features, i.e. information such as:

- Names (authors or others)
- Names of the institutes (hospitals, medical schools, clinics...)
- Cities

Also not authorised

- Trademarks. The use of commercial drug names, brands and registered trademarks is strictly prohibited. Instead, use generic drug names. Drugs should be referred to by their active substances or pharmacological designations.
- Company names and locations
- Websites and email addresses

Failure to comply with the above requirements will/may lead to automatic rejection of the submission, or this information may be deleted by the abstract services, and/or some rephrasing may occur.

Our mission: to reduce the burden of cardiovascular disease. 

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIÉTÉ EUROPÉENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

Furthermore, the Abstract Reviewing Committee (graders) is required to identify abstracts pertaining to commercial promotion of a proprietary product, to notify the Scientific Committee.

Do not include grant acknowledgements in the abstract content. Use the appropriate field (see Funding acknowledgements section above).

Reference list and bibliography – Please use this field to enter references and/or citations relevant to your submission. Do not list references/citations in the body text.

Keywords – Limit use of acronyms and abbreviations. Define at first use with the acronym or abbreviation in parentheses after the full word. Abbreviations increase the difficulty of reading and evaluating abstracts, which will be considered in the review process. Only commonly used abbreviations should appear in the title of the abstract. Do not include copyright or trademark symbols.

Please note that any medical research involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association. If any human experimentation is undertaken, the presenting author must be able to provide copies of informed consents signed by human participants. We remind you that a patient's photo should be avoided, and the patient must never be identifiable in your submission/presentation.

Step 4: Abstract Preview and Submission

Proofread abstracts carefully to avoid errors before submission, check spelling and grammar. The abstract will be reviewed and published (if accepted) as it has been submitted – No Exceptions!

Do not forget to click on the 'submit' button to validate your abstract submission. After having submitted your abstract, you will receive an immediate automatic confirmation by email (please make sure to state your correct email address!). If you do not receive this confirmation, please contact us at mpd2026@medpoint.de.

There is no limit to the number of abstracts an author/individual may submit, but the same research cannot be submitted twice/in separate abstracts, even under a different topic/category or with a different title. If you submit two abstracts with the same content, the Abstract Submission Services will automatically keep the most recent abstract submitted and withdraw the other. Note that duplicate abstracts will not be deleted.

Abstract grading/results – All abstracts will be blinded for review by 5 to 10 members of the Abstract Reviewing Committee (graders). Each grader is selected by the Scientific Committee to review abstracts in the topics that best fit their expertise.

Our mission: to reduce the burden of cardiovascular disease.

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIETE EUROPEENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

Our intent is to be most inclusive of the quality science received without compromising scientific integrity.

NB – The Abstract Reviewing Committee (graders) is required to identify abstracts pertaining to commercial promotion of a proprietary product, to notify the Scientific Committee.

Abstracts submitted for consideration must be an original idea, concept, or an improvement or revision of a previous idea. Submissions are peer-reviewed for scientific content, logical presentation, and current interest of the topic to the scientific community.

The final selection will be made by the Scientific Committee, which will determine the format and schedule of presentation for each abstract. No rescheduling or changes will be possible.

Accepted abstracts will be scheduled either as Oral presentations or Poster presentations. Presentation and interaction on the research will be conducted in English. Presenters are expected to speak/write good English.

Authors will be notified by email whether their abstract has been accepted or rejected. Please ensure that the email address provided is accurate, as all correspondence will be sent via email.

If the abstract is accepted, the final reference number and session assigned to each poster, as well as further instructions, will be communicated by email before the beginning of the meeting.

Presentation policy – Submission of an abstract constitutes a formal commitment by the author(s) to present the work in-person, if accepted. Failure to register for the Meeting by the set deadline will lead to the withdrawal of the abstract from the scientific programme and all publications (if applicable).

The same presenter cannot be assigned to more than 3 abstracts – co-authors should then be assigned as presenters.

All expenses (registration, travel, hotel...) associated with the submission and presentation of an abstract are under the responsibility of the presenter.

Publication of abstracts – All presented abstracts will be published online on the ESC 365 event page.

Embargo – Accepted abstracts are under embargo until one week before the meeting. Submitted abstracts should not be published in any other journals and/or online publications or presented at any international congresses. Breaking of the Embargo Policy by a presenter or co-author will lead to the withdrawal of the abstract/presentation from the Scientific Programme and retraction from all ESC publications. For more information about the ESC Media and Embargo Policy, please consult the full version online – <https://www.escardio.org/The-ESC/Press-Office/ESC-Media-and-Embargo-Policy>

Our mission: to reduce the burden of cardiovascular disease.

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIETE EUROPEENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

Affirmation of originality and copyright transfer statement

By submitting your work to the ESC:

- You consent to have authors' names, affiliation and biographical material used in connection with the publication of your work.
- Author(s) represents and warrants to the ESC that he/she/they is/are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, and that the work is original and does not infringe upon any copyright, proprietary, or personal right of any third party. The submitter hereby affirms that the work submitted is original, except for extracts from copyrighted works fully authorised by the copyright holders, and that all statements declared as facts are based on thorough examination and investigation for accurateness.
- Submitted abstracts should not have been published in any other journals and/or online publications nor presented at any previous international congress. However, former presentation at national meetings and/or non-cardiovascular specialists' meetings does not disqualify. A submitter, presenter or co-author submitting or presenting published work will lead to the withdrawal of the abstract/presentation from the Scientific Programme.
- Submitted abstracts must report new information not previously published or presented at a national or international scientific meeting prior to the Meeting. Note that abstracts previously presented at meetings will not be accepted unless there is a substantial update of data.

The content belongs to the author(s). However, if the abstract is accepted the submitter agrees, on behalf of all co-authors, to transfer and assign to the ESC free of charge, on a non-exclusive basis, for twenty years from the present submission the rights to edit, publish, reproduce, reformat, distribute in whole or in part the abstract and prepare all types of derivative works such as press releases and/or educational products, using all communication tools and means, now known or hereinafter developed, including any and all digital means and any and all supports or forms of media, now known or hereinafter developed, in particular all paper, analog, digital, numerical and electronic media, including Internet, Intranet and Extranet sites and social media. This includes use in indexes or search databases in print, electronic, or other media.

The authors retain the right, after presentation, to subsequently include the work in articles, books, or derivative works that he/she authors or edits, provided said use does not imply the endorsement of the ESC.

Our mission: to reduce the burden of cardiovascular disease.

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIETE EUROPEENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

The submitter signs for all co-authors. He/she accepts responsibility for the present rules for submission and presentation on behalf of all co-authors.

Disclosure Policy/Conflict(s) of interest

The Scientific Committee requests all presenters to disclose their potential conflict(s) of interest at the time of acceptance of presentation.

It is also the responsibility of the presenter to disclose any potential conflict(s) of interest from co-authors pertaining to the presentation on the presentation itself (as may be required).

This will allow the audience to take potential conflicts of interest into account when assessing the objectivity of the presentation.

A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, investments and stock ownership, funding for research, family relationship, etc. All related potential conflicts of interest must be stated.

This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations.

Data privacy

By certifying that you have read these Submission rules, you also confirm having received prior approval from the co-authors to provide their data for processing in connection with M&PD 2026. The information collected in this CALL FOR ABSTRACTS is subject to data processing to proceed with the elaboration of the Scientific programme. It is a statutory requirement to list the authors who have contributed to the research submitted. Authors not listed in the submission will not be acknowledged in the abstract if accepted for publication and presentation at the Meeting and in the promotion of the abstract.

The recipients of the data are the M&PD 2026 Organisational Team (medpoint GmbH), ESC Staff who process the submissions, and the ESC Committees and volunteers involved in the scientific programme. Data collected will be kept for 20 years. Transfer of personal data occurs for production, promotion and dissemination of the Meeting content.

In accordance with Chapter 3 of the European Regulation 2016/679 with regard to data protection, you have the right to request access to and rectification or erasure of your personal

Our mission: to reduce the burden of cardiovascular disease.

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIETE EUROPEENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075

data, or restriction of processing concerning your data, or to object to processing, as well as the right to data portability. This is done through withdrawal of the abstract according to the terms and conditions of withdrawal.

For data privacy concerns regarding your M&PD 2026 submission, please contact mpd2026@medpoint.de.

You have the right to lodge a complaint with a supervisory authority.

Applicable law – All the rules pertaining to the present submission rules are governed by, and construed in accordance with, the laws of France, without regard to any conflicts of laws principles thereof that would require the application of the law of any other jurisdiction. Any disputes arising in relation hereto shall be submitted to the exclusive jurisdiction of the French Tribunal Judiciaire located in Grasse, France.

The ESC reserves the right to make changes to the Abstract submission rules based on the convention centre restrictions/protocols/requirements and/or in case of exceptional/Force Majeure events (defined as unforeseeable and irresistible events beyond control of the ESC, such as natural disasters, war, civil unrest, coup d'État....).

Any update or change will be posted on the M&PD 2026 website (<https://medpoint.de/mpd-abstracts>).

If you have difficulties in submitting your abstract(s) or if you need any further information, please contact us at mpd2026@medpoint.de.

Our mission: to reduce the burden of cardiovascular disease. 

Headquarters: The European Heart House - Les Templiers - 2035, Route des Colles - CS 80179 BIOT - 06903 Sophia Antipolis Cedex - France
Tel. +33 (0)4 92 94 76 00 - escardio.org

ESC Brussels Office: 34 Rue de la Loi - 6th floor - B-1040 Brussels - Belgium - Tel. +32 (0)2 274 10 70

SOCIÉTÉ EUROPÉENNE DE CARDIOLOGIE Association loi 1901 - Déclaration du 08/04/1992 N° 1/10006 J.O. N° 18 du 29/04/1992 - SIREN 403 299 480
Association immatriculée au registre des opérateurs de voyages n° IM006110075